116 related articles for article (PubMed ID: 37734979)
1. Development and evaluation of the MiCheck® Prostate test for clinically significant prostate cancer.
Shore ND; Polikarpov DM; Pieczonka CM; Henderson RJ; Bailen JL; Saltzstein DR; Concepcion RS; Beebe-Dimmer JL; Ruterbusch JJ; Levin RA; Wissmueller S; Le TH; Gillatt DA; Chan DW; Deng N; Siddireddy JS; Lu Y; Campbell DH; Walsh BJ
Urol Oncol; 2023 Nov; 41(11):454.e9-454.e16. PubMed ID: 37734979
[TBL] [Abstract][Full Text] [Related]
2. Development and evaluation of the MiCheck test for aggressive prostate cancer.
Shore ND; Pieczonka CM; Henderson RJ; Bailen JL; Saltzstein DR; Concepcion RS; Beebe-Dimmer JL; Ruterbusch JJ; Levin RA; Wissmueller S; Le TH; Gillatt D; Chan DW; Campbell DH; Walsh BJ
Urol Oncol; 2020 Aug; 38(8):683.e11-683.e18. PubMed ID: 32305266
[TBL] [Abstract][Full Text] [Related]
3. A comparison of prostate health index, total PSA, %free PSA, and proPSA in a contemporary US population-The MiCheck-01 prospective trial.
Shore ND; Pieczonka CM; Henderson RJ; Bailen JL; Saltzstein DR; Concepcion RS; Beebe-Dimmer JL; Ruterbusch JJ; Le TH; Levin RA; Wissmueller S; Prah P; Borotkanics R; Paivanas TA; van Breda A; Campbell DH; Walsh BJ
Urol Oncol; 2020 Aug; 38(8):683.e1-683.e10. PubMed ID: 32360170
[TBL] [Abstract][Full Text] [Related]
4. PI-RADS 3 lesions: Does the association of the lesion volume with the prostate-specific antigen density matter in the diagnosis of clinically significant prostate cancer?
Rico L; Blas L; Vitagliano G; Contreras P; Rios Pita H; Ameri C
Urol Oncol; 2021 Jul; 39(7):431.e9-431.e13. PubMed ID: 33221259
[TBL] [Abstract][Full Text] [Related]
5. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
[TBL] [Abstract][Full Text] [Related]
6. Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore.
Verbeek JFM; Bangma CH; Kweldam CF; van der Kwast TH; Kümmerlin IP; van Leenders GJLH; Roobol MJ
Urol Oncol; 2019 Feb; 37(2):138-144. PubMed ID: 30528698
[TBL] [Abstract][Full Text] [Related]
7. The use of 29 MHz transrectal micro-ultrasound to stratify the prostate cancer risk in patients with PI-RADS III lesions at multiparametric MRI: A single institutional analysis.
Avolio PP; Lughezzani G; Paciotti M; Maffei D; Uleri A; Frego N; Hurle R; Lazzeri M; Saita A; Guazzoni G; Casale P; Buffi NM
Urol Oncol; 2021 Dec; 39(12):832.e1-832.e7. PubMed ID: 34183255
[TBL] [Abstract][Full Text] [Related]
8. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential.
Ström P; Nordström T; Aly M; Egevad L; Grönberg H; Eklund M
Eur Urol; 2018 Aug; 74(2):204-210. PubMed ID: 29331214
[TBL] [Abstract][Full Text] [Related]
9. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
Haese A; Dworschack RT; Partin AW
J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
[TBL] [Abstract][Full Text] [Related]
10. Utility of free/total prostate specific antigen (f/t PSA) ratio in diagnosis of prostate carcinoma.
Thakur V; Singh PP; Talwar M; Mukherjee U
Dis Markers; 2003-2004; 19(6):287-92. PubMed ID: 15258330
[TBL] [Abstract][Full Text] [Related]
11. Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study.
Brown LC; Ahmed HU; Faria R; El-Shater Bosaily A; Gabe R; Kaplan RS; Parmar M; Collaco-Moraes Y; Ward K; Hindley RG; Freeman A; Kirkham A; Oldroyd R; Parker C; Bott S; Burns-Cox N; Dudderidge T; Ghei M; Henderson A; Persad R; Rosario DJ; Shergill I; Winkler M; Soares M; Spackman E; Sculpher M; Emberton M
Health Technol Assess; 2018 Jul; 22(39):1-176. PubMed ID: 30040065
[TBL] [Abstract][Full Text] [Related]
12. Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.
Van Neste L; Hendriks RJ; Dijkstra S; Trooskens G; Cornel EB; Jannink SA; de Jong H; Hessels D; Smit FP; Melchers WJ; Leyten GH; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; Hulsbergen-van de Kaa CA; Mulders PF; van Oort IM; Van Criekinge W; Schalken JA
Eur Urol; 2016 Nov; 70(5):740-748. PubMed ID: 27108162
[TBL] [Abstract][Full Text] [Related]
13. A urine-based Exosomal gene expression test stratifies risk of high-grade prostate Cancer in men with prior negative prostate biopsy undergoing repeat biopsy.
McKiernan J; Noerholm M; Tadigotla V; Kumar S; Torkler P; Sant G; Alter J; Donovan MJ; Skog J
BMC Urol; 2020 Sep; 20(1):138. PubMed ID: 32873277
[TBL] [Abstract][Full Text] [Related]
14. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
15. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy.
McKiernan J; Donovan MJ; Margolis E; Partin A; Carter B; Brown G; Torkler P; Noerholm M; Skog J; Shore N; Andriole G; Thompson I; Carroll P
Eur Urol; 2018 Dec; 74(6):731-738. PubMed ID: 30237023
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of two on-line risk calculators versus the detection of circulating prostate cells for the detection of high risk prostate cancer at first biopsy.].
Murray NP; Fuentealba C; Reyes E; Jacob O
Arch Esp Urol; 2017 Jun; 70(5):503-512. PubMed ID: 28613202
[TBL] [Abstract][Full Text] [Related]
18. Clinical usefulness of free PSA in early detection of prostate cancer.
Luboldt HJ; Swoboda A; Börgermann C; Fornara P; Rübben H;
Onkologie; 2001 Feb; 24(1):33-7. PubMed ID: 11441278
[TBL] [Abstract][Full Text] [Related]
19. Clinical validation of IsoPSA, a single parameter, structure-focused assay for improved detection of prostate cancer: A prospective, multicenter study.
Klein EA; Partin A; Lotan Y; Baniel J; Dineen M; Hafron J; Manickam K; Pliskin M; Wagner M; Kestranek A; Stovsky M
Urol Oncol; 2022 Sep; 40(9):408.e9-408.e18. PubMed ID: 35840465
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of prostate cancer diagnosis by machine learning techniques: an algorithm development and validation study.
Chiu PK; Shen X; Wang G; Ho CL; Leung CH; Ng CF; Choi KS; Teoh JY
Prostate Cancer Prostatic Dis; 2022 Apr; 25(4):672-676. PubMed ID: 34267331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]